Saturday 17 October 2026 Export CRSP’s income statement to Excel — free account

CRISPR Therapeutics AG

CRISPR Therapeutics AG’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 90.6% from fiscal 2024. In the quarter to June 2026, revenue grew 1,041.4%, EPS grew 60.8% and free cash flow grew 26.2%, each against the same quarter a year earlier.

49.30 2.22 −4.31%

Follow CRSP

Alert me

Market cap: $5.0B
P/E: 0.0×
Fwd P/E: −10.8×
Dividend yield: —
F-score: 2/9
Altman Z: 7.04
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 14.84

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	1	3	2	9	—	1	—	—	—	2	3

Insider Ownership 6.99%

Capital & Financial Ratios $m

Market Cap 4,980.00

Revenue 13.39

Net Income (451.14)

Free Cash Flow (371.32)

Net Debt (1,778.15)

Current Ratio 17.85

Debt/Equity 0.34

P/E ratio 0.00

Fwd P/E (10.80)

P/S ratio 355.30

P/B ratio 2.72

Past 5Y EPS Growth —

This Y EPS Growth 32.31%

Next Y EPS Growth 23.48%

Next Y revenue growth 1,052.14%

Next 5Y EPS Growth 32.04%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 75.34%

10-year low 10-year high

P/B against its own 10 years 41.65%

10-year low 10-year high

EV/Sales against its own 10 years 74.33%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	1,694	1,904	1,976	2,364
Receivables	200	25	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	1,908	1,937	1,986	2,372

	2023	2024	2025	Q'26
Payables	38	15	11	11
ST’ Debt	—	—	—	—
Other	5	10	13	17
	109	88	149	133

Compound Annual Growth %

	10y	5y	3y
Sales	30.40%	37.31%	43.09%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	2.92%	0.82%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	1	10	—	—	—
’25	1	1	1	1	4
’24	1	1	1	36	37
’23	100	70	—	201	371
’22	1	0	0	0	1
’21	1	901	1	13	915
’20	0	0	0	0	1

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(109)	(83)	—	—	—
’25	(54)	(114)	(85)	(93)	(345)
’24	110	(96)	(107)	(50)	(143)
’23	9	(133)	(40)	(96)	(260)
’22	(135)	(142)	(105)	(113)	(496)
’21	(101)	807	(81)	(86)	539
’20	(52)	(29)	(76)	(81)	(238)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(109)	(84)	—	—	—
’25	(54)	(114)	(85)	(93)	(346)
’24	109	(96)	(107)	(50)	(145)
’23	6	(137)	(42)	(97)	(270)
’22	(151)	(152)	(111)	(120)	(533)
’21	(108)	779	(118)	(95)	457
’20	(55)	(33)	(81)	(87)	(257)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.28)	(0.94)	—	—	—
’25	(1.58)	(2.40)	(1.17)	(1.37)	(6.47)
’24	(1.43)	(1.49)	(1.01)	(0.44)	(4.34)
’23	(0.67)	(0.98)	(1.41)	1.10	(1.94)
’22	(2.32)	(2.40)	(2.24)	(1.41)	(8.36)
’21	(1.51)	9.44	(1.67)	(1.84)	4.70
’20	(1.15)	(1.30)	(1.32)	(1.50)	(5.29)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	13.75	11.63	22.22	27.15	32.30	67.15	38.94	37.55	38.20	30.04	Analyst estimates 2026–2028 Powerpack
	High	23.97	25.00	73.90	74.00	181.42	220.20	86.95	76.97	91.10	78.48
People
People	Employees	93	127	188	304	410	473	458	407	393	0
	Revenue/emp, $m	0.06	0.32	0.02	0.95	0.00	1.93	0.00	0.91	0.09	0.00
Income, $m
Income, $m	Revenue	5	41	3	290	1	915	1	371	37	4
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	(23)	(67)	(164)	67	(348)	380	(650)	(151)	(363)	(578)
	EBT margin, %	(439.93)	(162.47)	(5,263.38)	23.24	(48,408.34)	41.48	(54,298.83)	(40.60)	(971.93)	(16,466.24)
	Net income	(23)	(68)	(165)	67	(349)	378	(650)	(154)	(366)	(582)
	Depreciation	1	3	4	5	11	18	24	20	19	19
Per share, $
Per share, $	Revenue	0.42	1.02	0.07	5.32	0.01	12.05	0.02	4.69	0.44	0.04
	Earnings	(1.89)	(1.71)	(3.44)	1.23	(5.29)	4.97	(8.36)	(1.94)	(4.34)	(6.47)
	Cash flow	(4.51)	(1.75)	(2.01)	1.04	(3.61)	7.10	(6.38)	(3.29)	(1.69)	(3.84)
	Capex	(0.25)	(0.20)	(0.06)	(0.12)	(0.28)	(1.08)	(0.48)	(0.12)	(0.02)	(0.01)
	Free cash flow	(4.76)	(1.94)	(2.06)	0.92	(3.89)	6.02	(6.85)	(3.41)	(1.71)	(3.85)
	Book value	19.00	4.69	8.18	17.27	25.23	31.59	24.12	23.77	22.90	21.37
	Shares, m	12	40	48	54	66	76	78	79	84	90
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	54.87	0.00	15.19	0.00	0.00	0.00	0.00
	P/S	53.41	24.59	438.65	11.44	14,043.96	6.29	2,660.79	14.10	88.98	1,343.49
	P/B	1.18	5.37	3.49	3.53	6.07	2.40	1.70	2.78	1.72	2.45
	EV/Sales	(7.69)	18.74	292.47	8.33	11,762.55	3.92	1,335.82	10.15	44.05	845.25
	EV/FCF	0.68	(9.86)	(9.23)	48.27	(32.94)	7.85	(3.00)	(13.96)	(11.36)	(8.58)
Cash, $m
Cash, $m	Operating cash flow	(55)	(70)	(96)	57	(238)	539	(496)	(260)	(143)	(345)
	Capex	(3)	(8)	(3)	(7)	(18)	(82)	(37)	(9)	(2)	(1)
	Free cash flow	(58)	(78)	(99)	50	(257)	457	(533)	(270)	(145)	(346)
Balance, $m
Balance, $m	Working capital	298	234	439	930	1,622	2,298	1,732	1,799	1,849	1,837
	Total debt	—	—	—	44	50	213	228	—	—	—
	Net debt	(316)	(240)	(457)	(944)	(1,690)	(2,379)	(1,815)	(1,694)	(1,904)	(1,976)
	Shareholders’ equity	233	188	392	939	1,664	2,399	1,875	1,883	1,932	1,922
Returns, %
Returns, %	ROA	(9.19)	(22.18)	(43.40)	8.59	(24.10)	16.49	(26.03)	(6.87)	(16.38)	(25.81)
	ROIC	0.00	0.00	0.00	0.00	0.00	1,148.27	(699.33)	(73.55)	(1,032.08)	0.00
	ROE	(22.75)	(32.50)	(56.89)	10.04	(26.80)	18.59	(30.42)	(8.17)	(19.20)	(30.18)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
MIRM Mirum Pharmaceuticals, Inc.	$5.4B	— (loss-making)	— (loss-making)	+37.92% (above 0%: growing)	n/m	−681.46% (below 0%: shrinking)	82.78%	(24.14%)	Compare
ERAS Erasca, Inc.	$5.2B	— (loss-making)	—	—	n/m	−4.67% (below 0%: shrinking)	0.00%	0.00%	Compare
COGT Cogent Biosciences, Inc.	$5.1B	— (loss-making)	— (loss-making)	−69.41% (below 0%: shrinking)	n/m	−42.01% (below 0%: shrinking)	0.00%	0.00%	Compare
PTCT PTC Therapeutics, Inc.	$5.1B	— (loss-making)	110×	+101.55% (above 0%: growing)	n/m	+295.69% (above 0%: growing)	94.47%	41.32%	Compare
CRSP CRISPR Therapeutics AG	$5.0B	— (loss-making)	— (loss-making)	+1,041.37% (above 0%: growing)	n/m	+26.19% (above 0%: growing)	100.00%	(1,151.84%)
TVTX Travere Therapeutics, Inc.	$5.0B	— (loss-making)	196×	+48.17% (above 0%: growing)	n/m	+604.22% (above 0%: growing)	98.72%	2.33%	Compare
SRRK Scholar Rock Holding Corporation	$5.0B	— (loss-making)	— (loss-making)	+605.03% (above 0%: growing)	n/m	+8.88% (above 0%: growing)	0.00%	0.00%	Compare
ORKA Oruka Therapeutics, Inc.	$4.9B	— (loss-making)	—	—	n/m	−43.00% (below 0%: shrinking)	0.00%	0.00%	Compare
DFTX Definium Therapeutics, Inc.	$4.6B	— (loss-making)	—	—	n/m	−78.31% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$5.0B	—	—	+48.17%	—	−23.34%	0.00%	0.00%

All 614 Biotechnology stocks →

CRISPR Therapeutics AG (CRSP) key facts

Concern: CRISPR Therapeutics AG’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 90.6% from fiscal 2024.
Concern: CRISPR Therapeutics AG reported a net loss of $581.6 million, or a loss of $6.47 per share, for fiscal 2025.
CRISPR Therapeutics AG (CRSP) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, CRSP traded at $49.30, a market capitalization of $5.0 billion.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 355× sales.
Return on equity was −30.2% and debt-to-equity 0.34.
Its Piotroski F-score is 2 out of 9 and its Altman Z-score is 7.04 (safe zone) for fiscal 2025.